ArticleMicrobiological research2025
Role of R5 pyocin in the predominance of high-risk Pseudomonas aeruginosa isolates.
Article in Microbiological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond the Usual Suspects: EmergingInternational journal of molecular sciences · 2026Review
- R pyocin sensitivity ofJournal of medical microbiology · 2026Article
- Lipopolysaccharide-targeting treatments for multidrug-resistantExpert opinion on therapeutic targets · 2026Review
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
Infections with antimicrobial-resistant pathogens, such as Pseudomonas aeruginosa, are a frequent occurrence in healthcare settings. Although human P. aeruginosa infections are predominantly caused by a small number of sequence types (ST), such as ST235 and ST111, that are frequently multidrug-resistant, the basis for this dominance remains unclear. Using a genome-wide, transposon-insertion library screen, we discovered that the production of R5 pyocins (one of 5 subtypes of R pyocins) confers a competitive advantage to ST111 strains. Competitive dominance was lost by mutants lacking R pyocin production. Analysis of 5135 P. aeruginosa strains revealed that several international, high-risk sequence types (including ST235 and ST111) are enriched for R5 pyocin production, indicating a correlation between R5 pyocin production and clinical dominance, suggesting a novel approach for evaluating risk from emerging P. aeruginosa strains. An ST235 strain also lost its competitive advantage after deletion of an R5 pyocin structural gene, corroborating these findings. Overall, our study sheds light onto mechanisms underlying predominance of particular clades of antimicrobial resistant bacteria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.